Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
de Novo Myelodysplastic Syndromes: early-phase trial registry
A small indexed set (11 trials) with no open enrollment listed right now.
Corpus placement: #1,577 of 28,707 conditions by registered trial count.
11 US clinical trials · none currently recruiting · #1,577 of 28,707 conditions by registered trial count
de Novo Myelodysplastic Syndromes: 11 US clinical trials tracked, none currently recruiting.
de Novo Myelodysplastic Syndromes is the subject of 11 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 3 are in Phase 3-4 (later-stage) and 7 in Phase 1-2 (earlier-stage). The most active sponsor is Children's Oncology Group, running 3 of these trials.
Enrollment posture brief
Registry condition de-novo-myelodysplastic-syndromes
OPEN 0 | RECR 0% | LATE 3 | EARLY 7 | RANK #1577 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
de Novo Myelodysplastic Syndromes has no open enrollment in this registry pull (11 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for de Novo Myelodysplastic Syndromes on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
de Novo Myelodysplastic Syndromes is recruiting below its size-band peers.
0 of 11 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates de Novo Myelodysplastic Syndromes research.
Children's Oncology Group accounts for 3 of 11 trials (27.3%). 6 distinct sponsors appear on at least one study for this condition label.
-
Most de Novo Myelodysplastic Syndromes trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 11 trials that report a genuine target (sentinel values excluded). 9 of those (81.8%) plan for fewer than 100 participants.
-
de Novo Myelodysplastic Syndromes research is mostly interventional.
11 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Indexed trials (enrollment closed)
11 total, page 1 of 1
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome
National Cancer Institute (NCI)
NCT00002798
Supersaturated Calcium Phosphate Rinse in Preventing Oral Mucositis in Young Patients Undergoing Autologous or Donor Stem Cell Transplant
Children's Oncology Group
NCT01305200
CCI-779 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, or Chronic Myelogenous Leukemia in Blastic Phase
National Cancer Institute (NCI)
NCT00084916
Tipifarnib in Treating Patients With Myelodysplastic Syndromes
National Cancer Institute (NCI)
NCT00005845
Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
NCT00445744
Clofarabine, Cytarabine, and Filgrastim in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome, and/or Advanced Myeloproliferative Neoplasm
University of Washington
NCT01101880
Bendamustine and Idarubicin in Treating Older Patients With Previously Untreated AML or MDS
Fred Hutchinson Cancer Center
NCT01141725
Etanercept in Treating Young Patients With Idiopathic Pneumonia Syndrome After Undergoing a Donor Stem Cell Transplant
Children's Oncology Group
NCT00309907
Organ-Sparing Marrow-Targeted Irradiation Before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies
Sumithira Vasu
NCT02122081
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases
Children's Oncology Group
NCT00450450
Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
University of Wisconsin, Madison
NCT01707004
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 4 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on de Novo Myelodysplastic Syndromes records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on de Novo Myelodysplastic Syndromes trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this de Novo Myelodysplastic Syndromes page
11 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No de Novo Myelodysplastic Syndromes trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Children's Oncology Group sponsors the most de Novo Myelodysplastic Syndromes trials on record, review their full trial history before evaluating a specific study. See Children's Oncology Group's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This de Novo Myelodysplastic Syndromes condition card totals 11 registered trials; most-linked intervention tacrolimus; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.